Lung Cancer

Tecentriq plus carboplatin and pemetrexed may improve efficacy in patients with NSCLC with untreated brain metastases, according to results of a phase 2 trial.

Benmelstobart plus anlontinib with a chemotherapy combination improved survival outcomes for patients with extensive-stage small cell lung cancer.

During chemotherapy, strawberry-flavored Boost and baked potatoes were the only things I would eat — but this nourishment ended up representing much more.

The first patients in a phase 1/2 trial have received a combination of HPN328, an immunotherapy, and Tecentriq for small cell lung cancer.

Living with stage 4 cancer begs reflection. Have I lived my life with purpose? How will I be remembered? Did I do all I wanted to do?

When combined with Keytruda, the novel drug, NC318, proved to be safe and efficacious in treating advanced non-small cell lung cancer, research showed.

Tedopi, a novel lung cancer vaccine, demonstrated improved survival and safety profile, according to preliminary findings from a phase 3 trial.

The treatment combination of Imfinzi plus radiotherapy is “promising” for certain patients with NSCLC, according to preliminary findings from a trial.

Treatment with perioperative Imfinzi plus neoadjuvant chemotherapy may improve surgery outcomes for patients with resectable non-small cell lung cancer.

As The Los Angeles Rams celebrate a cancer survivor and a 9/11 survivor reveals his fourth cancer diagnosis, this is what’s happening in the oncology space this week.

Adding Imfinzi the pre- and post-surgical treatment for patients with non-small cell lung cancer led to improved results, research showed.

The three-drug combination of Tagrisso plus platinum-based chemotherapy and pemetrexed boosted outcomes for patients with EGFR-mutant advanced non-small cell lung cancer.

Data revealed promising results for the combination of Trodelvy and Keytruda as a first-line treatment for patients with metastatic non-small cell lung cancer.

The TROPION-Lung04 trial reveals improvements from combining Dato-DXd with Imfinzi with or without carboplatin for patients with previously untreated advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations.

The phase 2 ARROS-1 trial will investigate NVL-520 in patients with pretreated ROS1-positive non-small cell lung cancer or other solid tumors.

The phase 3 MARIPOSA- 2 study shows significant improvement within progression free survival after implementing Rybrevant into treatment for patients with non-small cell lung cancer.

For three-and-a-half years, my cancer was stable.

Patients treated with 12 months of Lixiana, an anticoagulant therapy, received a greater benefit than those treated with three months of the therapy.

The addition of Tumor Treating Fields to standard therapy tended to improve overall survival in patients with pretreated metastatic non-small cell lung cancer.

The use of Gavreto is shown to be effective and very well-tolerated in patients with metastatic RET fusion-positive NSCLC, according to an expert.

When asked for recommended treatments for certain types of cancer, ChatGPT missed the mark about one-third of the time, research showed.

Someone was watching over me the day I was diagnosed with non-small cell lung cancer.

The Oncologic Drug Advisory Committee will review data to determine if Lumakras should gain FDA approval for certain patients with KRAS G12C-mutant non-small cell lung cancer.

Chemoimmunotherapy was tested in patients with extensive-stage small cell lung cancer to determine its effect based on different performance statuses.

I am a big believer in the proverbial toolbox.

The members of my lung cancer support group recently came up with some responses for when people ask us, "So you have lung cancer — did you smoke?"

Don’t waste your cancer.

This regular approval provides Gavreto as a treatment option for patients with metastatic RET fusion-positive non-small cell lung cancer.

Tecentriq, compared with chemotherapy, improved survival while maintaining quality-of-life in patients with non-small cell lung cancer considered ineligible for platinum-based chemotherapy.

Researchers conducting this trial will compare zipalertinib plus chemotherapy with chemotherapy alone in patients with previously untreated, locally advanced or metastatic non-small cell lung cancer with the EGFR exon 20 insertion mutation.